{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:27:54Z","timestamp":1793647674736,"version":"4.5.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal","id":[{"id":"https:\/\/ror.org\/02xzytt36","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tuberculosis (TB) and chronic kidney disease (CKD) are interconnected global health concerns. CKD patients have a higher risk of developing TB. Decreased clearance of drugs in kidney disease enhances toxicity risk. Current guidance on medication doses is not based on therapeutic drug monitoring. We measured and compared the concentrations of first-line anti-TB drugs in CKD and those with normal kidney function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective observational study was conducted from September 2020 to December 2023. Patients with microbiologically confirmed tuberculosis were included, and drug concentrations were determined by using Liquid Chromatography-Tandem Mass Spectrometer (LC-MS\/MS) and compared between CKD and those with normal kidney function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 151 participants, 51 had CKD. Higher trough concentrations were found in CKD for isoniazid [697.15 ng\/mL (IQR 199.07\u20133321.68) vs. 187.58 ng\/mL (IQR 95.56\u2013323.65),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001], rifampicin [141.53 ng\/mL (IQR 40.86\u2013730.66) vs. 33.24 ng\/mL (IQR 22.49\u201386.20),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001], and ethambutol [635.67 ng\/mL (IQR 264.38\u20131594.12) vs. 230.92 ng\/mL (IQR 161.95\u2013417.22),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001], while pyrazinamide level [1469.79 ng\/mL (IQR 0.00\u20135160.53) vs. 4273.94 ng\/mL (IQR 2151.29\u20138023.81),\n                      <jats:italic>P\u2009=<\/jats:italic>\n                      \u20090.002] was higher in those with normal kidney function. At 2-hours, a greater number of CKD patients had below the reference threshold for rifampicin [33\/51 (64.7%) vs. 48\/100 (48%),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.059] and pyrazinamide [39\/40 (97.5%) vs. 29\/91 (31.8%),\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.0001].\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CKD affects anti-tubercular drug concentrations, highlighting the need for therapeutic drug monitoring.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration number<\/jats:title>\n                    <jats:p>CTRI\/2020\/09\/027951.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-026-02931-7","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T07:48:04Z","timestamp":1788162484000},"page":"2835-2850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of kidney function on drug concentrations of first-line anti-tubercular treatment"],"prefix":"10.1007","volume":"54","author":[{"given":"Divya","family":"Datta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indu Ramachandra","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghavendra","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar Prasad","family":"Nagaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Thunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Magazine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivashankara Kaniyoor","family":"Nagri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha Abdul","family":"Khader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasumarthi","family":"Tejashree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surulivelrajan","family":"Mallayasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Kumar","family":"Tirlangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharshan","family":"Rangaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivas Vinayak","family":"Shenoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan V.","family":"Bhojaraja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5980-7197","authenticated-orcid":false,"given":"Attur Ravindra","family":"Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2931_CR1","unstructured":"Evaluation CKD. and Management \u2013 KDIGO [Internet]. [cited 2024 Oct 2]. Available from: https:\/\/kdigo.org\/guidelines\/ckd-evaluation-and-management\/"},{"key":"2931_CR2","unstructured":"India TBR. 2023 \u2013 Central Tuberculosis Division [Internet]. [cited 2024 Sep 17]. Available from: https:\/\/tbcindia.mohfw.gov.in\/2023\/06\/06\/india-tb-report-2023\/"},{"issue":"1","key":"2931_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1186\/s12879-019-4010-7","volume":"19","author":"N Saito","year":"2019","unstructured":"Saito N, Yoshii Y, Kaneko Y, Nakashima A, Horikiri T, Saito Z, et al. Impact of renal function-based anti-tuberculosis drug dosage adjustment on efficacy and safety outcomes in pulmonary tuberculosis complicated with chronic kidney disease. BMC Infect Dis. 2019;19(1):374. https:\/\/doi.org\/10.1186\/s12879-019-4010-7 . PubMed PMID: 31046706; PubMed Central PMCID: PMC6498605.","journal-title":"BMC Infect Dis"},{"key":"2931_CR4","unstructured":"National Institute for Health and Care Excellence. The Guidelines Manual [Internet]. London: National Institute for Health and Care Excellence (NICE); 2012 [cited 2023 Aug 30]. (NICE Process and Methods Guides). Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK395866\/ PubMed PMID: 27905714."},{"issue":"5","key":"2931_CR5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.5588\/ijtld.18.0225","volume":"23","author":"PJY Cho","year":"2019","unstructured":"Cho PJY, Wu CY, Johnston J, Wu MY, Shu CC, Lin HH. Progression of chronic kidney disease and the risk of tuberculosis: an observational cohort study. Int J Tuberc Lung Dis. 2019;23(5):555\u201362. https:\/\/doi.org\/10.5588\/ijtld.18.0225 . PubMed PMID: 31097063.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"2931_CR6","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/qjmed\/hcu220","volume":"108","author":"TC Shen","year":"2015","unstructured":"Shen TC, Huang KY, Chao CH, Wang YC, Muo CH, Wei CC, et al. The risk of chronic kidney disease in tuberculosis: a population-based cohort study. QJM. 2015;108(5):397\u2013403. https:\/\/doi.org\/10.1093\/qjmed\/hcu220 . PubMed PMID: 25352683.","journal-title":"QJM"},{"issue":"4","key":"2931_CR7","first-page":"221","volume":"39","author":"P Gurumurthy","year":"1992","unstructured":"Gurumurthy P, Raghupati Sarma G, Jayasankar K, Thyagarajan K, Prabhakar R, Muthusethupathi MA, et al. Single-dose pharmacokinetics of isoniazid and rifampicin in patients with chronic renal failure. Indian J Tuberculosis. 1992;39(4):221\u20138.","journal-title":"Indian J Tuberculosis"},{"issue":"15","key":"2931_CR8","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.2165\/00003495-200262150-00001","volume":"62","author":"CA Peloquin","year":"2002","unstructured":"Peloquin CA. Therapeutic Drug Monitoring in the Treatment of Tuberculosis. Drugs. 2002;62(15):2169\u201383. https:\/\/doi.org\/10.2165\/00003495-200262150-00001.","journal-title":"Drugs"},{"issue":"10","key":"2931_CR9","first-page":"1487","volume":"75","author":"MY Munar","year":"2007","unstructured":"Munar MY, Singh H. Drug dosing adjustments in patients with chronic kidney disease. Am Fam Physician. 2007;75(10):1487\u201396. PubMed PMID: 17555141.","journal-title":"Am Fam Physician"},{"issue":"7","key":"2931_CR10","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1093\/cid\/ciz380","volume":"70","author":"G Ramachandran","year":"2020","unstructured":"Ramachandran G, Chandrasekaran P, Gaikwad S, Agibothu Kupparam HK, Thiruvengadam K, Gupte N, et al. Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes. Clin Infect Dis. 2020;70(7):1463\u201370. https:\/\/doi.org\/10.1093\/cid\/ciz380 . PubMed PMID: 31075166; PubMed Central PMCID: PMC7931830.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2931_CR11","doi-asserted-by":"publisher","first-page":"106297","DOI":"10.1016\/j.ijantimicag.2021.106297","volume":"57","author":"A Trentalange","year":"2021","unstructured":"Trentalange A, Borgogno E, Motta I, Antonucci M, Pirriatore V, Costa C, et al. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses? Int J Antimicrob Agents. 2021;57(3):106297. https:\/\/doi.org\/10.1016\/j.ijantimicag.2021.106297.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"2931_CR12","doi-asserted-by":"publisher","first-page":"2392883","DOI":"10.1080\/0886022X.2024.2392883","volume":"46","author":"D Datta","year":"2024","unstructured":"Datta D, Rao IR, Prabhu AR, Nagaraju SP, Thunga G, Magazine R, et al. Effect of chronic kidney disease on adverse drug reactions to anti-tubercular treatment: a retrospective cohort study. Ren Fail. 2024;46(2):2392883. 2024.2392883 PubMed PMID: 39165235; PubMed Central PMCID: PMC11340219.","journal-title":"Ren Fail"},{"key":"2931_CR13","unstructured":"Guideline for PMDT in India. 2017 \u2013 Central Tuberculosis Division [Internet]. [cited 2024 Sep 24]. Available from: https:\/\/tbcindia-wp.azurewebsites.net\/guideline-for-pmdt-in-india-2017-3\/"},{"key":"2931_CR14","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1\u2013150. Available from: https:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/KDIGO_2012_CKD_GL.pdf"},{"issue":"8","key":"2931_CR15","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s40265-014","volume":"74","author":"A Alsultan","year":"2014","unstructured":"Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: an update. Drugs. 2014;74(8):839\u201354. https:\/\/doi.org\/10.1007\/s40265-014-. 0222-8 PubMed PMID: 24846578.","journal-title":"Drugs"},{"issue":"RR\u201311","key":"2931_CR16","first-page":"1","volume":"52","author":"Infectious Diseases Society of America","year":"2003","unstructured":"Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52(RR\u201311):1\u201377.","journal-title":"MMWR Recomm Rep"},{"key":"2931_CR17","unstructured":"Central Tuberculosis Division. India TB Annual Report 2023. New Delhi: Ministry of Health and Family Welfare, Government of India. 2023. Available from: https:\/\/tbcindia.mohfw.gov.in"},{"issue":"7","key":"2931_CR18","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1093\/ndt\/gfr624","volume":"27","author":"ND Vaziri","year":"2012","unstructured":"Vaziri ND, Yuan J, Rahimi A, Ni Z, Said H, Subramanian VS. Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transpl. 2012;27(7):2686\u201393. https:\/\/doi.org\/10.1093\/ndt\/gfr624 . PubMed PMID: 22131233; PubMed Central PMCID: PMC3616758.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"2931_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1053\/j.ackd.2006.10.001","volume":"14","author":"FEM Murtagh","year":"2007","unstructured":"Murtagh FEM, Addington-Hall J, Higginson IJ. The Prevalence of Symptoms in End-Stage Renal Disease: A Systematic Review. Adv Chronic Kidney Dis. 2007;14(1):82\u201399. https:\/\/doi.org\/10.1053\/j.ackd.2006.10.001 . PubMed PMID: 17200048.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"8","key":"2931_CR20","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1517\/17425255.4.8.1065","volume":"4","author":"AW Dreisbach","year":"2008","unstructured":"Dreisbach AW, Lertora JJL. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol. 2008;4(8):1065\u201374. https:\/\/doi.org\/10.1517\/17425255.4.8.1065 . PubMed PMID: 18680441; PubMed Central PMCID: PMC2745294.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"2931_CR21","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1525-139x.2010","volume":"23","author":"TD Nolin","year":"2010","unstructured":"Nolin TD, Unruh ML. Clinical relevance of impaired nonrenal drug clearance in ESRD. Semin Dial. 2010;23(5):482\u20135. https:\/\/doi.org\/10.1111\/j.1525-139x.2010. 00775.x PubMed PMID: 21069923.","journal-title":"Semin Dial"},{"issue":"7","key":"2931_CR22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00228-007-0305-5","volume":"63","author":"PR Donald","year":"2007","unstructured":"Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, Werely CJ, et al. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol. 2007;63(7):633\u20139. https:\/\/doi.org\/10.1007\/s00228-007-0305-5 . PubMed PMID: 17505821.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"2931_CR23","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","volume":"69","author":"J Azuma","year":"2013","unstructured":"Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, et al. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: A randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol. 2013;69(5):1091\u2013101. https:\/\/doi.org\/10.1007\/s00228-012-1429-9.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"2931_CR24","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/clpt.2008.59","volume":"83","author":"TD Nolin","year":"2008","unstructured":"Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther. 2008;83(6):898\u2013903. https:\/\/doi.org\/10.1038\/clpt.2008.59 . PubMed PMID: 18388866.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2931_CR25","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3109\/00365548.2011.647832","volume":"44","author":"A Shaheen","year":"2012","unstructured":"Shaheen A, Najmi MH, Saeed W, Farooqi ZUR. Pharmacokinetics of standard dose regimens of rifampicin in patients with pulmonary tuberculosis in Pakistan. Scand J Infect Dis. 2012;44(6):459\u201364. https:\/\/doi.org\/10.3109\/00365548.2011.647832 . PubMed PMID: 22224832.","journal-title":"Scand J Infect Dis"},{"issue":"10","key":"2931_CR26","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1093\/jac\/dku210","volume":"69","author":"JB Prahl","year":"2014","unstructured":"Prahl JB, Johansen IS, Cohen AS, Frimodt-M\u00f8ller N, Andersen \u00c5B. Clinical significance of 2\u00a0h plasma concentrations of first-line anti-tuberculosis drugs: a prospective observational study. J Antimicrob Chemother. 2014;69(10):2841\u20137. https:\/\/doi.org\/10.1093\/jac\/dku210 . PubMed PMID: 25140577.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2931_CR27","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/jac\/dkw534","volume":"72","author":"C Sekaggya-Wiltshire","year":"2017","unstructured":"Sekaggya-Wiltshire C, von Braun A, Scherrer AU, Manabe YC, Buzibye A, Muller D, et al. Anti-TB drug concentrations and drug-associated toxicities among TB\/HIV-coinfected patients. J Antimicrob Chemother. 2017;72(4):1172\u20137. https:\/\/doi.org\/10.1093\/jac\/dkw534 . PubMed PMID: 28108678; PubMed Central PMCID: PMC5703350.","journal-title":"J Antimicrob Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02931-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02931-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02931-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:49:54Z","timestamp":1793645394000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02931-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2931"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02931-7","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}